Bucindolol

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems[1][2] but not in human hearts.[3][4] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[5]

Bucindolol
Clinical data
ATC code
  • none
Identifiers
  • 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethyl-ethyl]amino]propoxy]benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.114.291
Chemical and physical data
FormulaC22H25N3O2
Molar mass363.461 g·mol−1
3D model (JSmol)
  • N#Cc0ccccc0OCC(O)CNC(C)(C)Cc1c[nH]c2c1cccc2

See also

References
  1. "formularyjournal.modernmedicine.com". Archived from the original on 2012-03-04.
  2. Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185. S2CID 46848815.
  3. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ (December 1998). "The role of third-generation beta-blocking agents in chronic heart failure". Clinical Cardiology. 21 (S1): I3–I13. doi:10.1002/clc.4960211303. PMC 6656140. PMID 9853189.
  4. Hershberger RE, Wynn JR, Sundberg L, Bristow MR (June 1990). "Mechanism of Action of Bucindolol in Human Ventricular Myocardium". Journal of Cardiovascular Pharmacology. 15 (6): 959–967. doi:10.1097/00005344-199006000-00014. PMID 1694919.
  5. "FDA rejects bucindolol and questions trial integrity « CardioBrief". 2 June 2009.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.